The Rare Disease Coalition is strengthening its work with UCB as a new partner in its efforts to improve the quality of life and health of patients with rare diseases.
The Coalition for Rare Diseases is moving from 4 to 5 biotech companies, making it a stronger voice for a better framework for the medical treatment of rare diseases.
"We are very pleased that the UCB sees the value of standing together in a field that has been mistreated in Norwegian prioritization policy for far too long. This makes it easier to speak with one voice to politicians and administrators, say the Coalition members.
UCB's ambition is to transform the lives of people living with serious diseases so that they can live the best life they can - as free as possible from the challenges and uncertainties of disease. This commitment comes to life in our research and development activities across neurology, immunology and other areas where our expertise, innovation and ambition match unmet needs.
UCB is continuously working to advance science and embrace new knowledge, bringing passion and leadership to solve the challenges that matter to people living with serious diseases. We leverage scientific advances and new technologies in areas including genetics, biomarkers and human biology. Continually inspired by those we serve to bring differentiated solutions with unique outcomes that deliver tangible, positive impact.